Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ricoderm-GN is a topical combination medication developed by Oscorp Remedies, designed to treat inflammatory skin conditions complicated by bacterial and fungal infections. The formulation contains clobetasol propionate, a high-potency corticosteroid that provides rapid relief from inflammation, redness, and itching; neomycin sulphate, an aminoglycoside antibiotic that addresses secondary bacterial infections; and miconazole nitrate, an imidazole antifungal agent effective against a broad spectrum of fungi. This triple-action approach makes Ricoderm-GN suitable for managing complex dermatological conditions such as infected eczema, psoriasis, and various forms of dermatitis where a multi-pronged therapeutic strategy is required.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clobetasol propionate + miconazole nitrate + neomycin sulphate.